<p>CureVac N.V.（纳斯达克代码：CVAC - 获取免费报告）在七月份的空头头寸大幅下降。截至 7 月 31 日，空头头寸总计 741,700 股，比 7 月 15 日的 1,060,000 股下降了 30.0%。该股票约有 0.8% 的股份被做空。根据平均交易量 1,210,000 股，目前的覆盖天数比率为 0.6 天。</p>
<h2>CureVac 价格表现</h2>
<ul>
<li>2 只小盘股在牛市中有望大放异彩</li>
</ul>
<p>纳斯达克 CVAC 周三开盘价为 5.46 美元。该公司的 50 日简单移动平均为 5.42 美元，200 日简单移动平均为 4.11 美元。CureVac 的 52 周低点为 2.37 美元，52 周高点为 5.72 美元。该公司的债务与股本比率为 0.05，速动比率为 7.64，流动比率为 6.17。该股票的市值为 12.2 亿美元，市盈率为 5.69，贝塔值为 2.53。</p>
<p>CureVac（纳斯达克代码：CVAC - 获取免费报告）最近于 8 月 21 日发布了季度财报。该公司报告本季度每股收益为（0.30 美元），低于分析师一致预期的（0.15 美元）15 美分。CureVac 的股本回报率为 29.57%，净利润率为 38.21%。该公司本季度的收入为 141 万美元，而分析师预期为 427 万美元。分析师预计 CureVac 在当前财政年度的每股收益为 0.72 美元。</p>
<h2>分析师评级上调与下调</h2>
<ul>
<li>3 只股票适合在 COVID 复苏中购买</li>
</ul>
<p>CVAC 成为多份研究分析师报告的主题。Citizens JMP 在 6 月 12 日的报告中将 CureVac 的评级从 “强烈买入” 下调至 “持有”。瑞银集团在 6 月 26 日的研究报告中将 CureVac 的股票评级从 “强烈买入” 下调至 “中性”，并将其目标价从 12.00 美元下调至 5.50 美元。花旗集团在 6 月 12 日的研究报告中将 CureVac 的股票评级下调至 “市场表现”。JMP 证券在 5 月 28 日的报告中重申了 “市场跑赢大盘” 的评级，并对 CureVac 的股票设定了 10.00 美元的目标价。最后，杰富瑞金融集团在 6 月 13 日的研究报告中重新发布了 “持有” 评级，并将 CureVac 的目标价设定为 5.00 美元（之前为 7.00 美元）。一位股票研究分析师对该股票给予了买入评级，四位分析师给予了持有评级。根据 MarketBeat，该公司目前的共识评级为 “持有”，共识目标价为 6.83 美元。</p>
<p><strong>阅读我们对 CureVac 的最新分析</strong></p>
<h2>机构资金流入与流出</h2>
<p>一些机构投资者和对冲基金最近增加或减少了对 CVAC 的持股。Alpine Associates Management Inc.在第二季度购买了 CureVac 的新股份，价值为 10,703,000 美元。Qube Research &amp; Technologies Ltd 在第二季度获得了 CureVac 的新头寸，价值为 6,419,000 美元。Water Island Capital LLC 在第二季度获得了 CureVac 的新头寸，价值为 5,197,000 美元。摩根大通在第二季度获得了 CureVac 的新头寸，价值为 1,705,000 美元。最后，GSA Capital Partners LLP 在第一季度获得了 CureVac 的新头寸，价值为 853,000 美元。17.26% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 CureVac</h2>
<p>（获取免费报告）</p>
<p>CureVac N.V.是一家生物制药公司，专注于开发基于信使核糖核酸（mRNA）的各种变革性药物。它正在开发预防性疫苗，如针对 SARS-CoV-2 的 mRNA 疫苗候选者 CV2CoV，目前处于第一阶段临床试验；CV7202 用于狂犬病治疗，处于第一阶段临床试验；以及 CVSQIV 用于治疗多价季节性流感；Flu SV mRNA 用于治疗核苷酸、单抗季节性流感。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票超过 CureVac</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>Archer 的飞行里程碑和防御胜利令华尔街兴奋</li>
<li>TSX 风险投资交易所（前加拿大风险投资交易所）</li>
<li>Upstart 股票可能会因短期挤压而上涨</li>
<li>如何从成长投资中获利</li>
<li>这只铁路股票正在向新的历史高点迈进</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 CureVac 吗？</h2>
<p>在考虑 CureVac 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 CureVac 并不在名单上。</p>
<p>虽然 CureVac 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CVAC

<p>CureVac N.V.（纳斯达克代码：CVAC）在短期空头头寸方面经历了显著下降，7 月份下降了 30.0%，降至 741,700 股。这代表了公司被卖空股份的 0.8%，根据 121 万股的平均交易量，短期空头头寸比率为 0.6 天。该股票开盘价为 5.46 美元，市值为 12.2 亿美元，市盈率为 5.69。分析师的评级意见不一，普遍评级为 “持有”，目标价为 6.83 美元。机构投资者持有该股票的 17.26%</p>

<p>CureVac N.V. (NASDAQ:CVAC - Get Free Report) was the target of a large drop in short interest in July. As of July 31st, there was short interest totaling 741,700 shares, adropof30.0% from the July 15th total of 1,060,000 shares. Approximately0.8% of the shares of the stock are short sold. Based on an average trading volume of 1,210,000 shares, the days-to-cover ratio is presently 0.6 days. Based on an average trading volume of 1,210,000 shares, the days-to-cover ratio is presently 0.6 days. Approximately0.8% of the shares of the stock are short sold.</p>
<div class="lb-trans"><p>CureVac N.V.（纳斯达克代码：CVAC - 获取免费报告）在七月份的空头头寸大幅下降。截至 7 月 31 日，空头头寸总计 741,700 股，比 7 月 15 日的 1,060,000 股下降了 30.0%。该股票约有 0.8% 的股份被做空。根据平均交易量 1,210,000 股，目前的覆盖天数比率为 0.6 天。</p>
</div><h2>CureVac Price Performance</h2>
<div class="lb-trans"><h2>CureVac 价格表现</h2>
</div><ul>
<li>2 Small-Cap Stocks Set to Shine in a Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只小盘股在牛市中有望大放异彩</li>
</ul>
</div><p>NASDAQ CVAC opened at $5.46 on Wednesday. The business has a 50 day simple moving average of $5.42 and a 200 day simple moving average of $4.11. CureVac has a 52-week low of $2.37 and a 52-week high of $5.72. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.64 and a current ratio of 6.17. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of 5.69 and a beta of 2.53.</p>
<div class="lb-trans"><p>纳斯达克 CVAC 周三开盘价为 5.46 美元。该公司的 50 日简单移动平均为 5.42 美元，200 日简单移动平均为 4.11 美元。CureVac 的 52 周低点为 2.37 美元，52 周高点为 5.72 美元。该公司的债务与股本比率为 0.05，速动比率为 7.64，流动比率为 6.17。该股票的市值为 12.2 亿美元，市盈率为 5.69，贝塔值为 2.53。</p>
</div><p>CureVac (NASDAQ:CVAC - Get Free Report) last released its quarterly earnings results on Thursday, August 21st. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.15). CureVac had a return on equity of 29.57% and a net margin of 38.21%.The firm had revenue of $1.41 million for the quarter, compared to analyst estimates of $4.27 million. Analysts anticipate that CureVac will post 0.72 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>CureVac（纳斯达克代码：CVAC - 获取免费报告）最近于 8 月 21 日发布了季度财报。该公司报告本季度每股收益为（0.30 美元），低于分析师一致预期的（0.15 美元）15 美分。CureVac 的股本回报率为 29.57%，净利润率为 38.21%。该公司本季度的收入为 141 万美元，而分析师预期为 427 万美元。分析师预计 CureVac 在当前财政年度的每股收益为 0.72 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><ul>
<li>3 Stocks to Buy For the COVID Resurgence</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只股票适合在 COVID 复苏中购买</li>
</ul>
</div><p>CVAC has been the subject of a number of research analyst reports. Citizens Jmp lowered CureVac from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, June 12th. UBS Group downgraded shares of CureVac from a &#34;strong-buy&#34; rating to a &#34;neutral&#34; rating and dropped their price target for the stock from $12.00 to $5.50 in a research note on Thursday, June 26th. Citigroup downgraded shares of CureVac to a &#34;market perform&#34; rating in a research note on Thursday, June 12th. JMP Securities reiterated a &#34;market outperform&#34; rating and issued a $10.00 price objective on shares of CureVac in a report on Wednesday, May 28th. Finally, Jefferies Financial Group reissued a &#34;hold&#34; rating and set a $5.00 target price (down previously from $7.00) on shares of CureVac in a research report on Friday, June 13th. One equities research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $6.83.</p>
<div class="lb-trans"><p>CVAC 成为多份研究分析师报告的主题。Citizens JMP 在 6 月 12 日的报告中将 CureVac 的评级从 “强烈买入” 下调至 “持有”。瑞银集团在 6 月 26 日的研究报告中将 CureVac 的股票评级从 “强烈买入” 下调至 “中性”，并将其目标价从 12.00 美元下调至 5.50 美元。花旗集团在 6 月 12 日的研究报告中将 CureVac 的股票评级下调至 “市场表现”。JMP 证券在 5 月 28 日的报告中重申了 “市场跑赢大盘” 的评级，并对 CureVac 的股票设定了 10.00 美元的目标价。最后，杰富瑞金融集团在 6 月 13 日的研究报告中重新发布了 “持有” 评级，并将 CureVac 的目标价设定为 5.00 美元（之前为 7.00 美元）。一位股票研究分析师对该股票给予了买入评级，四位分析师给予了持有评级。根据 MarketBeat，该公司目前的共识评级为 “持有”，共识目标价为 6.83 美元。</p>
</div><p><strong>Read Our Latest Analysis on CureVac</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 CureVac 的最新分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in CVAC. Alpine Associates Management Inc. bought a new stake in shares of CureVac during the 2nd quarter valued at $10,703,000. Qube Research &amp; Technologies Ltd acquired a new position in shares of CureVac during the 2nd quarter worth $6,419,000. Water Island Capital LLC acquired a new position in shares of CureVac during the 2nd quarter worth $5,197,000. JPMorgan Chase &amp; Co. acquired a new position in shares of CureVac during the 2nd quarter worth $1,705,000. Finally, GSA Capital Partners LLP acquired a new position in shares of CureVac during the 1st quarter worth $853,000. 17.26% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近增加或减少了对 CVAC 的持股。Alpine Associates Management Inc.在第二季度购买了 CureVac 的新股份，价值为 10,703,000 美元。Qube Research &amp; Technologies Ltd 在第二季度获得了 CureVac 的新头寸，价值为 6,419,000 美元。Water Island Capital LLC 在第二季度获得了 CureVac 的新头寸，价值为 5,197,000 美元。摩根大通在第二季度获得了 CureVac 的新头寸，价值为 1,705,000 美元。最后，GSA Capital Partners LLP 在第一季度获得了 CureVac 的新头寸，价值为 853,000 美元。17.26% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About CureVac</h2>
<div class="lb-trans"><h2>关于 CureVac</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.</p>
<div class="lb-trans"><p>CureVac N.V.是一家生物制药公司，专注于开发基于信使核糖核酸（mRNA）的各种变革性药物。它正在开发预防性疫苗，如针对 SARS-CoV-2 的 mRNA 疫苗候选者 CV2CoV，目前处于第一阶段临床试验；CV7202 用于狂犬病治疗，处于第一阶段临床试验；以及 CVSQIV 用于治疗多价季节性流感；Flu SV mRNA 用于治疗核苷酸、单抗季节性流感。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than CureVac</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>Archer's Flight Milestones &amp; Defense Wins Excite Wall Street</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>Upstart Stock Could Pop on a Short Squeeze Soon</li>
<li>How to Profit From Growth Investing</li>
<li>This Railroad Stock Is Chugging Along to a New All-Time High</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 CureVac</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>Archer 的飞行里程碑和防御胜利令华尔街兴奋</li>
<li>TSX 风险投资交易所（前加拿大风险投资交易所）</li>
<li>Upstart 股票可能会因短期挤压而上涨</li>
<li>如何从成长投资中获利</li>
<li>这只铁路股票正在向新的历史高点迈进</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CureVac Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 CureVac 吗？</h2>
</div><p>Before you consider CureVac, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CureVac 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 CureVac 并不在名单上。</p>
</div><p>While CureVac currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CureVac 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

CureVac N.V.（纳斯达克股票代码：CVAC）的空头头寸减少了 30.0%